tradmap

TLRY Tilray Brands

$2.54 +0.40%

Data as of close

Cannabis Stocks

Healthcare · Medicinal Chemicals & Botanical Products

Tilray Brands (TLRY) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $375 million. Shares last traded at $2.54, 83.8% below their 52-week high. Over the past year the stock is down 80.2%. Net profit margin is -17.1%, below the peer median of -8.8%. Revenue grew 11.5% year over year.

Market Cap
$375M
Shares Out
147.8M
EPS (TTM)
-$1.41
P/E (TTM)*
—
P/S Ratio
0.39
P/B Ratio
0.23
Dividend / Share
—
Dividend Yield
—
52-Week High
$15.69
52-Week Low
$2.49
Volume (venue)
221,121
Avg Vol (3m, venue)
234,041.032

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-6.96%
1M
-29.44%
3M
-45.38%
6M
-57.02%
YTD
-71.96%
1Y
-80.16%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. TLRY split history →

Technicals

RSI (14)
18.20
SMA (50)
$3.74
SMA (200)
$5.44
Price vs SMA50
-32.12%
Price vs SMA200
-53.30%
ATR (14)
$0.15

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$963M
Net Income
-$164M
Gross Margin
29.1%
Operating Margin
-9.3%
Net Margin
-17.1%
Return on Equity
-10.1%
Return on Assets
-7.1%
Current Ratio
1.88
Debt / Equity
0.07
Revenue Growth (YoY)
+11.5%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-08-31. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q1 2027 -$0.32 2026-10-08
Q4 2026 (derived) -$0.44 2026-07-28
FY 2026 -$1.09 2026-07-28
Q3 2026 -$0.24 2026-04-01
Q2 2026 -$0.41 2026-01-08
Q1 2026 $0.00 2025-10-09

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Medicinal Chemicals & Botanical Products peers

TLRY vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close

P/S vs peers
0.39 / 0.58 med
-33% discount
Net margin vs peers
-17.1% / -8.8% med
below median
1–14 of 14
DFTXDefinium Therapeutics, Inc.$4.4B———-10.70%
RGCRegencell Bioscience Holdings Ltd$3.1B———-5.00%
TRLVTrulieve Cannabis Corp.$2.1B—1.88-41.8%+8.19%
CRONCronos Group$1.2B17.646.8939.1%+1.52%
TLRYTilray Brands$375M—0.39-17.1%+0.40%
SNDLSNDL Inc.$337M———+2.81%
CGCCanopy Growth$288M—1.37-80.0%+4.07%
USNAUSANA HEALTH SCIENCES INC$271M—0.30-2.4%+2.69%
ACBAurora Cannabis$237M———+3.94%
GLASGlass House Brands Inc.$192M—1.05-16.3%+6.85%
NAGENiagen Bioscience, Inc.$190M11.881.4712.4%+2.56%
MDWDMediWound Ltd.$173M———+1.35%
FTLFFITLIFE BRANDS, INC.$78M12.450.776.2%+4.69%
BTMDbiote Corp.$33M5.560.183.2%+1.79%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.